APRE – aprea therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Form SCHEDULE 13G Aprea Therapeutics, Inc. Filed by: Nantahala Capital Management, LLC
Form 8-K Aprea Therapeutics, Inc. For: Nov 08
Form 424B5 Aprea Therapeutics, Inc.
Form 8-K Aprea Therapeutics, Inc. For: Nov 07
Form 10-Q Aprea Therapeutics, Inc. For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.